- Trial phase
- Phase 3
- Time to market
- At least 2-3 years assuming successful Phase 3 readout and regulatory filing; could be accelerated if FDA allows filing based on Phase 1 data under Breakthrough Therapy Designation, but no such filing has been announced.
- Why 4/10
- Zoldonrasib's Phase 3 RASolute 305 trial (1L metastatic PDAC) began enrolling in June 2026; a primary readout is likely 2-3 years away. No PDUFA date or accelerated filing announced despite Breakthrough Therapy Designation. The next hard binary catalyst is >12 months out, capping the score at 5. Recent Phase 1/2 data presentations (AACR Apr 2026, ESMO GI Jul 2026) have already been absorbed by the market.
Zoldonrasib is a promising next-gen KRAS G12D inhibitor with impressive Phase 1 data, but the next hard catalyst (Phase 3 readout) is years away. The stock RVMD trades near ~$187 with a consensus price target of ~$193, much of the near-term value already reflects strong daraxonrasib (RMC-6236) Phase 3 data in pancreatic cancer. Watch for regulatory filing updates given Breakthrough Therapy Designation, and enrollment updates for RASolute 305 and 309 trials. Short interest at ~6.25% of float with 4.3 days to cover adds optionality.
Price Chart
Executive Summary
Zoldonrasib is Revolution Medicines' investigational oral RAS(ON) G12D-selective covalent inhibitor for KRAS G12D-mutant cancers, a mutation for which no approved targeted therapy exists. The FDA granted Breakthrough Therapy Designation in January 2026 for previously treated KRAS G12D NSCLC based on Phase 1 data showing a 52% objective response rate, 93% disease control rate, and 11.1-month median progression-free survival. The drug is now entering Phase 3 development: the RASolute 305 trial (1L metastatic pancreatic cancer) began dosing in June 2026. Recent Phase 1/2 combo data at ESMO GI 2026 showed zoldonrasib + chemotherapy achieved up to 82% ORR in first-line PDAC. While early clinical data is compelling, the stock's recent 139% six-month rally partially reflects these catalysts, and the next binary Phase 3 readout is years away.
How It Works
Zoldonrasib is an oral targeted cancer therapy designed to attack a specific mutant form of the RAS protein called KRAS G12D, a common cancer driver found in pancreatic, lung, and colorectal cancers. It works by binding to the "active" (ON) form of the mutant protein and blocking its cancer-driving signals. It forms a tri-complex with a cellular protein (cyclophilin A) to lock the mutant RAS in an inactive state. Think of it as a key that only fits a specific broken lock (G12D mutation) found inside cancer cells.
Trial Status
Phase 3 RASolute 305 trial (NCT07621718) began treating patients in June 2026, a global, randomized, double-blind, placebo-controlled study evaluating zoldonrasib + chemo vs placebo + chemo in first-line metastatic KRAS G12D pancreatic cancer. Phase 1 monotherapy data in previously treated KRAS G12D NSCLC presented at AACR 2026 showed 52% ORR, 93% DCR, 11.1 months median PFS. Phase 1/2 combo data presented at ESMO GI July 2026 showed zoldonrasib + chemo ORR up to 82% in 1L PDAC and zoldonrasib + daraxonrasib ORR 47-50% in pretreated PDAC. A separate Phase 1/1b study (NCT06040541) in KRAS G12D solid tumors is ongoing.
The Two-Sided Case
Upcoming Catalysts
- Enrollment updates for RASolute 305 Phase 3 trial (1L metastatic PDAC)
- Potential regulatory filing strategy announcement given Breakthrough Therapy Designation
- Additional Phase 1/2 combo data at future medical conferences (ASCO, ESMO, AACR)
- Phase 3 RASolute 303 trial-in-progress updates for daraxonrasib (correlated pipeline value)
- Quarterly earnings reports with pipeline and regulatory updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Revolution Medicines, Inc. Press Release RVMD ·Originating report